As we observed the locus-dependent transcriptional defect after SETD1A degradation, an SETD1A inhibitor will provide a more specific tool for cancer therapy than CDK kinase inhibitors by modulating the CTD code on cancer-associated genes. Here, SETD1A is linked to cancer.